Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 8:36 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 2,669 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Control II Clear all
Completed No phase listed Observational

YSPSL for Prevention of Delayed Graft Function Part A

NCT00298181
View directory record Official record
Conditions
Delayed Graft Function
Interventions
YSPSL
Drug
Lead sponsor
Y's Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Tampa, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2008 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 3 Interventional Results available

American Ginseng in Treating Patients With Fatigue Caused by Cancer

NCT00719563
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Fatigue, Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
American ginseng, placebo
Drug · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
364 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
326
States / cities
Scottsdale, Arizona • Aurora, Colorado • Boulder, Colorado + 208 more
Source: ClinicalTrials.gov public record
Updated Feb 9, 2017 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 2 Interventional

Internet Intervention for Adolescents With Chronic Pain

NCT01316471
View directory record Official record
Conditions
Chronic Pain, Abdominal Pain, Headache
Interventions
Online Behavioral Intervention, Education: Online Patient Education
Behavioral · Other
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
11 Years to 17 Years
Enrollment
273 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 3, 2018 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study to Evaluate the Safety and Efficacy of Abatacept in Adults and Children 6 Years and Older With Excessive Loss of Protein in the Urine Due to Either Focal Segmental Glomerulosclerosis (FSGS) or Minimal Change Disease (MCD)

NCT02592798
View directory record Official record
Conditions
Nephrotic Syndrome, Focal Segmental Glomerulosclerosis, Minimal Change Disease
Interventions
Abatacept, Normal Saline, D5W
Drug · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
6 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
27
States / cities
Birmingham, Alabama • Torrance, California • Aurora, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Mar 5, 2021 · Synced Oct 30, 2026, 8:36 AM EDT
Terminated Phase 2 Interventional

Green Tea Extract in Treating Patients With Actinic Keratosis

NCT00005097
View directory record Official record
Conditions
Non-melanomatous Skin Cancer
Interventions
Polyphenon E and Placebo
Drug
Lead sponsor
Frank Meyskens
Other
Eligibility
18 Years and older
Enrollment
88 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 5, 2018 · Synced Oct 30, 2026, 8:36 AM EDT
Terminated Not applicable Interventional

The TANTALUS® II System for the Treatment of Type 2 Diabetes: A Randomized Study

NCT00547482
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Overweight
Interventions
TANTALUS(TM) System
Device
Lead sponsor
MetaCure (USA), Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
10
States / cities
La Jolla / San Diego, California • Los Angeles, California • Denver, Colorado + 6 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2010 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Not applicable Interventional

Hypnotherapy in Treating Chronic Pain in Cancer Survivors

NCT02637297
View directory record Official record
Conditions
Anxiety, Cancer Survivor, Chronic Pain, Depression, Sleep Disorder
Interventions
Hypnotherapy, Questionnaire Administration
Procedure · Other
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 21, 2017 · Synced Oct 30, 2026, 8:36 AM EDT
Not yet recruiting Not applicable Interventional

HOPE Intervention for Fitness

NCT07114822
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Harnessing Online Peer Education
Behavioral
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 8:36 AM EDT
Terminated Phase 2 Interventional Results available

Study to Compare the Effect of Ipilimumab Retreatment With That of Chemotherapy in Advanced Melanoma

NCT01709162
View directory record Official record
Conditions
Melanoma
Interventions
Ipilimumab, Chemotherapy
Biological · Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
7
States / cities
Birmingham, Alabama • Aurora, Colorado • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 30, 2015 · Synced Oct 30, 2026, 8:36 AM EDT
Recruiting Not applicable Interventional

Adaptive and Individualized AAC Phase II

NCT06337188
View directory record Official record
Conditions
Communication Disorders
Interventions
Experimental AAC, Generic AAC
Device
Lead sponsor
Altec Inc.
Industry
Eligibility
6 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Virtual Reality Experiences for Anxiety and Pain Control

NCT04759183
View directory record Official record
Conditions
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Virtual Reality Game, Virtual Reality Meditation
Other · Procedure
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 7, 2022 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Memantine Hydrochloride in Enhancing the Cognitive Abilities of Young Adults With Down Syndrome

NCT01112683
View directory record Official record
Conditions
Down Syndrome
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years to 32 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2013 · Synced Oct 30, 2026, 8:36 AM EDT
Terminated Not applicable Interventional Results available

"Answers in Hours" A Randomized Controlled Trial Using Microbiome Metagenomics for Bile Duct Cultures

NCT05523154
View directory record Official record
Conditions
Benign Pancreatic Neoplasm, Malignant Pancreatic Neoplasm
Interventions
Biospecimen Collection, Laboratory Procedure, Nanopore Sequencing
Procedure · Other · Device
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 18, 2025 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 2 Interventional Results available

Metformin Hydrochloride in Preventing Esophageal Cancer in Patients With Barrett Esophagus

NCT01447927
View directory record Official record
Conditions
Barrett Esophagus, Esophageal Cancer
Interventions
metformin hydrochloride, placebo
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
5
States / cities
Hines, Illinois • Rochester, Minnesota • Cleveland, Ohio + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2014 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 2 Interventional

Biological Therapy in Treating Patients Undergoing Radiation Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation for Hematologic Cancer

NCT00004061
View directory record Official record
Conditions
Leukemia, Lymphoma, Oral Complications
Interventions
filgrastim, palifermin, cyclophosphamide, etoposide, ifosfamide, peripheral blood stem cell transplantation, quality-of-life assessment, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 65 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2009
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 26, 2013 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

NSS-2-BRIDGE Study for Total Knee and Hip Arthroplasties, Bariatric, and Kidney Transplant Surgeries

NCT03834142
View directory record Official record
Conditions
Acute Pain, Arthropathy of Knee, Arthropathy of Hip, Pain, Postoperative, Kidney Transplant Donor, Bariatric Surgery Candidate
Interventions
NSS-2 Bridge
Device
Lead sponsor
Jacques E. Chelly
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2021
U.S. locations
3
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 2 Interventional Results available

Valganciclovir Therapy in Infants and Children With Congenital CMV Infection and Hearing Loss

NCT01649869
View directory record Official record
Conditions
Cytomegalovirus Infection
Interventions
Placebo, Valganciclovir
Other · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
1 Month to 4 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
9
States / cities
Birmingham, Alabama • Washington D.C., District of Columbia • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2024 · Synced Oct 30, 2026, 8:36 AM EDT
Terminated Phase 4 Interventional Results available

Addressing Cognitive Fog in Long-COVID-19 Patients

NCT05597722
View directory record Official record
Conditions
Cognitive Impairment, Long COVID
Interventions
Digital cognitive behavioral intervention-RxWell, Amphetamine-Dextroamphetamine
Behavioral · Drug
Lead sponsor
Eva Szigethy
Other
Eligibility
21 Years to 65 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 4 Interventional Results available

Quetiapine Augmentation for Treatment-resistant PTSD

NCT00292370
View directory record Official record
Conditions
Combat Disorders, Stress Disorders, Post-Traumatic
Interventions
Open Label (OL) Paroxetine, Placebo, Quetiapine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 75 Years
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
3
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Not applicable Interventional

Acupuncture in Treating Women With Stage I, Stage II, or Stage III Breast Cancer With Aromatase Inhibitor-Related Joint Pain

NCT01013337
View directory record Official record
Conditions
Breast Cancer, Recurrent Breast Cancer, Stage I Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
acupuncture therapy, sham intervention
Procedure
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced Oct 30, 2026, 8:36 AM EDT
Recruiting Phase 2 Interventional

Comparing the Radiopharmaceutical Drug, [177Lu]Lu-DOTATATE, to Standard of Care Treatment for Patients With Meningioma That Has Come Back After Prior Treatment

NCT06955169
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
[177Lu]Lu-DOTATATE, Standard of Care treatments
Drug · Other
Lead sponsor
RTOG Foundation, Inc.
Other
Eligibility
18 Years and older
Enrollment
130 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
17
States / cities
Irvine, California • La Jolla, California • New Haven, Connecticut + 13 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 30, 2026, 8:36 AM EDT
Terminated Phase 2 Interventional Results available

Bempegaldesleukin (NKTR-214) With Radiation and Anti-PD-1 Immunotherapy for Head and Neck Squamous Cell Carcinoma

NCT04936841
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
NKTR-214, anti-PD-1 therapy, Palliative Radiation
Drug · Radiation
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 4, 2024 · Synced Oct 30, 2026, 8:36 AM EDT
Terminated Phase 2Phase 3 Interventional

Study in Metastatic Breast Cancer Patients Receiving Eftilagimod Alpha or Placebo in Combination With Paclitaxel Chemotherapy

NCT05747794
View directory record Official record
Conditions
Breast Carcinoma
Interventions
eftilagimod alpha, Paclitaxel, placebo
Biological · Drug · Other
Lead sponsor
Immutep S.A.S.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
5
States / cities
Whittier, California • Washington D.C., District of Columbia • Rock Hill, South Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2026 · Synced Oct 30, 2026, 8:36 AM EDT
Completed Phase 2 Interventional

A Study of Bitopertin (RO4917838) in Combination With Selective Serotonin Reuptake Inhibitors (SSRIs) in Participants With Obsessive-Compulsive Disorder (OCD)

NCT01674361
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Bitopertin, Placebo, SSRI
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
99 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
27
States / cities
Oceanside, California • Stanford, California • New Haven, Connecticut + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 2, 2017 · Synced Oct 30, 2026, 8:36 AM EDT